| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3976676 | Brachytherapy | 2015 | 6 Pages |
Abstract
There is significant intra-prostatic dose heterogeneity in prostate HDR brachytherapy. This is most notable in the increased dose to base and lateral portions of the gland. Further studies are needed to determine the impact of heterogeneity on clinical outcomes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shane Mesko, Sang-June Park, Amar U. Kishan, D. Jeffrey Demanes, Mitchell Kamrava,